Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
BEXIMCO PHARMA.GDR REGS 1
R2WABeximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh. Address: 19 Dhanmondi R/A, Dhaka, Bangladesh, 1205
Analytics
WallStreetin tavoitehinta
–P/E-suhde
3.71Osinkotuotto
7.93 %Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut R2WA
Osinkoanalytiikka R2WA
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Osinkojen kasvu 5 vuoden aikana
109.00 %Jatkuva kasvu
1 vuosiMaksusuhde 5 vuoden keskiarvo
–Osinkohistoria R2WA
Osakkeen arvostus R2WA
Talousasiat R2WA
Tuloksia | 2019 | Dynamiikka |